Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice-Reference-Cited by-同舟云学术

Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice

Published:2009-05-01 Issue:5 Volume:90 Page:1119-1123
ISSN:0022-1317
Container-title:Journal of General Virology
language:en
Short-container-title:

Author:

Miao Congrong¹,Radu Gertrud U.¹,Caidi Hayat¹,Tripp Ralph A.²,Anderson Larry J.¹,Haynes Lia M.¹

Affiliation:

1. National Centers for Immunization and Respiratory Disease, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, Atlanta, GA 30333, USA

2. College of Veterinary Medicine, Department of Infectious Disease, University of Georgia, Athens, GA 30602, USA

Abstract

Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-γ) production in the lungs of RSV-infected mice. Its F(ab′)2 component only mediates decreased leukocyte trafficking and IFN-γ production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.

Publisher

Microbiology Society

Subject

Virology

Reference22 articles.

1. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies;Anderson;J Virol,1988

2. Pharmokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 125I or 111In;Brown;Cancer Res,1987

3. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2;Corbeil;Vaccine,1996

4. Respiratory syncytial virus and influenza A infections in the hospitalized elderly;Falsey;J Infect Dis,1995

5. Molecular diversity of the aminoterminal region of the G protein gene of human respiratory syncytial virus subgroup B;Fodha;Pathol Biol (Paris),2008

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence;The Journal of Immunology;2024-07-17

2. Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodies;Immunity;2024-07

3. Evolutionary trends of respiratory syncytial viruses: Insights from large-scale surveillance and molecular dynamics of G glycoprotein;Heliyon;2024-05

4. Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice;Nature Communications;2024-04-04

5. Microbiological and epidemiological features of respiratory syncytial virus;Revista Española de Quimioterapia;2024-03-21